PL3679042T3 - Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3Kdelta - Google Patents
Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3KdeltaInfo
- Publication number
- PL3679042T3 PL3679042T3 PL18853233.7T PL18853233T PL3679042T3 PL 3679042 T3 PL3679042 T3 PL 3679042T3 PL 18853233 T PL18853233 T PL 18853233T PL 3679042 T3 PL3679042 T3 PL 3679042T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazo
- pyrazine derivatives
- pi3kdelta
- inhibitors
- pi3kdelta inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017101058 | 2017-09-08 | ||
CN2017119373 | 2017-12-28 | ||
CN2018086555 | 2018-05-11 | ||
PCT/CN2018/104559 WO2019047915A1 (en) | 2017-09-08 | 2018-09-07 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3679042T3 true PL3679042T3 (pl) | 2023-09-04 |
Family
ID=65633578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18853233.7T PL3679042T3 (pl) | 2017-09-08 | 2018-09-07 | Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3Kdelta |
Country Status (21)
Country | Link |
---|---|
US (2) | US11220506B2 (pl) |
EP (2) | EP3679042B1 (pl) |
JP (1) | JP7128264B2 (pl) |
KR (1) | KR20200052297A (pl) |
CN (2) | CN111704615B (pl) |
AU (2) | AU2018328569B2 (pl) |
BR (1) | BR112020004500A2 (pl) |
CA (1) | CA3072842A1 (pl) |
DK (1) | DK3679042T3 (pl) |
ES (1) | ES2944658T3 (pl) |
FI (1) | FI3679042T3 (pl) |
HU (1) | HUE061898T2 (pl) |
IL (1) | IL272988B (pl) |
MX (1) | MX2020002630A (pl) |
NZ (1) | NZ761680A (pl) |
PL (1) | PL3679042T3 (pl) |
PT (1) | PT3679042T (pl) |
SG (1) | SG11202001286SA (pl) |
TW (2) | TWI817956B (pl) |
WO (1) | WO2019047915A1 (pl) |
ZA (1) | ZA202000875B (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7064495B2 (ja) | 2016-12-07 | 2022-05-10 | ベイジーン リミテッド | PI3Kδ阻害剤としてのイミダゾ[1,5-a]ピラジン誘導体 |
JP7128264B2 (ja) | 2017-09-08 | 2022-08-30 | ベイジーン リミテッド | PI3Kδ阻害剤としてのイミダゾ[1,5-a]ピラジン誘導体 |
TW202313617A (zh) * | 2021-05-27 | 2023-04-01 | 英屬開曼群島商百濟神州有限公司 | PI3Kδ抑制劑的鹽、其晶型、製備方法及用途 |
WO2023040810A1 (en) * | 2021-09-14 | 2023-03-23 | Beigene, Ltd. | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
CA2542481A1 (en) | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazopyrazine tyrosine kinase inhibitors |
WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
US8178529B2 (en) * | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
ES2475091T3 (es) * | 2009-04-16 | 2014-07-10 | Centro Nacional De Investigaciones Oncol�Gicas (Cnio) | Imidazopirazinas como inhibidores de proteína cinasas |
JP5766820B2 (ja) * | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
US9260435B2 (en) | 2012-01-10 | 2016-02-16 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines as Akt kinase inhibitors |
SI2914296T2 (sl) | 2012-11-01 | 2022-01-31 | Infinity Pharmaceuticals, Inc. | Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze |
SG11201509842SA (en) | 2013-05-30 | 2015-12-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
EP3057970A1 (en) * | 2013-10-18 | 2016-08-24 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
EP3179991B1 (en) * | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
AR102220A1 (es) * | 2015-10-08 | 2017-02-15 | Incyte Corp | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 |
MX2018015707A (es) * | 2016-06-16 | 2019-03-21 | Janssen Pharmaceutica Nv | Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta. |
JP7064495B2 (ja) * | 2016-12-07 | 2022-05-10 | ベイジーン リミテッド | PI3Kδ阻害剤としてのイミダゾ[1,5-a]ピラジン誘導体 |
JP7128264B2 (ja) | 2017-09-08 | 2022-08-30 | ベイジーン リミテッド | PI3Kδ阻害剤としてのイミダゾ[1,5-a]ピラジン誘導体 |
-
2018
- 2018-09-07 JP JP2020513700A patent/JP7128264B2/ja active Active
- 2018-09-07 SG SG11202001286SA patent/SG11202001286SA/en unknown
- 2018-09-07 CA CA3072842A patent/CA3072842A1/en active Pending
- 2018-09-07 EP EP18853233.7A patent/EP3679042B1/en active Active
- 2018-09-07 NZ NZ761680A patent/NZ761680A/en unknown
- 2018-09-07 TW TW107131522A patent/TWI817956B/zh active
- 2018-09-07 CN CN202010273331.8A patent/CN111704615B/zh active Active
- 2018-09-07 CN CN201880057835.7A patent/CN111051312A/zh active Pending
- 2018-09-07 ES ES18853233T patent/ES2944658T3/es active Active
- 2018-09-07 EP EP23152036.2A patent/EP4219502A1/en active Pending
- 2018-09-07 US US16/643,040 patent/US11220506B2/en active Active
- 2018-09-07 BR BR112020004500-4A patent/BR112020004500A2/pt unknown
- 2018-09-07 FI FIEP18853233.7T patent/FI3679042T3/fi active
- 2018-09-07 IL IL272988A patent/IL272988B/en unknown
- 2018-09-07 TW TW111147323A patent/TW202336010A/zh unknown
- 2018-09-07 HU HUE18853233A patent/HUE061898T2/hu unknown
- 2018-09-07 PL PL18853233.7T patent/PL3679042T3/pl unknown
- 2018-09-07 MX MX2020002630A patent/MX2020002630A/es unknown
- 2018-09-07 PT PT188532337T patent/PT3679042T/pt unknown
- 2018-09-07 KR KR1020207007386A patent/KR20200052297A/ko not_active Application Discontinuation
- 2018-09-07 DK DK18853233.7T patent/DK3679042T3/da active
- 2018-09-07 WO PCT/CN2018/104559 patent/WO2019047915A1/en unknown
- 2018-09-07 AU AU2018328569A patent/AU2018328569B2/en active Active
-
2020
- 2020-02-11 ZA ZA2020/00875A patent/ZA202000875B/en unknown
-
2021
- 2021-11-23 US US17/533,442 patent/US11905294B2/en active Active
-
2023
- 2023-10-25 AU AU2023254925A patent/AU2023254925A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1,5-a]吡嗪-4-基衍生物 | |
IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物 | |
IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound |